Earnings per share (EPS) increased to 2.42 cents in FY2023 from 2.30 cents a year ago on a fully diluted basis.
For the full-year period, revenue increased 9.4% y-o-y to $83.8 million mainly due to the increase in revenue of approximately $7.7 million from the company’s oncology services segment patient visits increased.
This was partially offset by the decrease in $0.5 million from TalkMed’s 60%-owned subsidiary, CellVec, for cellular and gene therapy related products and services.
As at end-December, cash and cash equivalents stood at $89.9 million.
See also: Creative guides for ‘similar level of operating loss’ for 2HFY2025
The group has proposed a final dividend of 1.3 cents for FY2023. Including the interim dividend of 0.9 cents paid out on Aug 22, 2023, this brings total dividends to 2.2 cents for the full-year period.
The final dividend will be paid on May 10.
Shares in TalkMed closed unchanged at 36.5 cents on Feb 20.
